BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nester CM, Smith RJ. Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens. 2013;22:231-237. [PMID: 23318699 DOI: 10.1097/mnh.0b013e32835da24c] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Meyers KE, Liapis H, Atta MG. American Society of Nephrology clinical pathological conference. Clin J Am Soc Nephrol 2014;9:818-28. [PMID: 24651072 DOI: 10.2215/CJN.12481213] [Reference Citation Analysis]
2 Abbas F, El Kossi M, Kim JJ, Shaheen IS, Sharma A, Halawa A. Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in de novo and recurrent diseases. World J Transplantation 2018; 8(6): 203-219 [PMID: 30370231 DOI: 10.5500/wjt.v8.i6.203] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT. C3 glomerulopathy: consensus report. Kidney Int 2013;84:1079-89. [PMID: 24172683 DOI: 10.1038/ki.2013.377] [Cited by in Crossref: 356] [Cited by in F6Publishing: 297] [Article Influence: 39.6] [Reference Citation Analysis]
4 Spartà G, Gaspert A, Neuhaus TJ, Weitz M, Mohebbi N, Odermatt U, Zipfel PF, Bergmann C, Laube GF. Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series. Clin Kidney J 2018;11:479-90. [PMID: 30094012 DOI: 10.1093/ckj/sfy006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Devalaraja-Narashimha K, Meagher K, Luo Y, Huang C, Kaplan T, Muthuswamy A, Halasz G, Casanova S, O'Brien J, Peyser Boiarsky R, McWhirter J, Gartner H, Bai Y, MacDonnell S, Liu C, Hu Y, Latuszek A, Wei Y, Prasad S, Huang T, Yancopoulos G, Murphy A, Olson W, Zambrowicz B, Macdonald L, Morton LG. Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy. J Am Soc Nephrol 2021;32:99-114. [PMID: 33288630 DOI: 10.1681/ASN.2020050698] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Sutherland LJ, Talreja H. C3-glomerulonephritis in New Zealand - a case series. BMC Nephrol 2020;21:399. [PMID: 32943008 DOI: 10.1186/s12882-020-02056-5] [Reference Citation Analysis]
7 Pirozzi N, Stoppacciaro A, Menè P. Dominant C3 glomerulopathy: new roles for an old actor in renal pathology. J Nephrol 2018;31:503-10. [PMID: 29151252 DOI: 10.1007/s40620-017-0458-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Mastellos DC, Reis ES, Ricklin D, Smith RJ, Lambris JD. Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends Immunol 2017;38:383-94. [PMID: 28416449 DOI: 10.1016/j.it.2017.03.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
9 Holdsworth SR, Gan PY, Kitching AR. Biologics for the treatment of autoimmune renal diseases. Nat Rev Nephrol 2016;12:217-31. [PMID: 26949177 DOI: 10.1038/nrneph.2016.18] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
10 Mella A, Messina M, Lavacca A, Biancone L. Complement cascade and kidney transplantation: The rediscovery of an ancient enemy. World J Transplant 2014; 4(3): 168-175 [PMID: 25346889 DOI: 10.5500/wjt.v4.i3.168] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
11 Trutin I, Oletić L, Galešić Ljubanović D, Turudić D, Milošević D. A CHILD WITH DENSE DEPOSIT DISEASE AND DECREASED CLASSIC COMPLEMENT PATHWAY ACTIVITY. Acta Clin Croat 2021;60:141-5. [PMID: 34588735 DOI: 10.20471/acc.2021.60.01.21] [Reference Citation Analysis]
12 Bettoni S, Bresin E, Remuzzi G, Noris M, Donadelli R. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. J Biol Chem. 2016;291:8214-8230. [PMID: 26903516 DOI: 10.1074/jbc.m115.693119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
13 Salvadori M, Rosso G. Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World J Nephrol 2016; 5(4): 308-320 [PMID: 27458560 DOI: 10.5527/wjn.v5.i4.308] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
14 Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, Amann K, Davin JC, Bouts AH, Schriemer PJ. Eculizumab in Pediatric Dense Deposit Disease. Clin J Am Soc Nephrol. 2015;10:1773-1782. [PMID: 26316621 DOI: 10.2215/cjn.01360215] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 5.4] [Reference Citation Analysis]
15 Prakash R, Ali US, Ohri A, Parekhji SN, Deokar A, Khubchandani S. Clinico-pathological Profile and Outcome of C-3 Glomerulopathy in Indian Children. Indian J Nephrol 2020;30:370-6. [PMID: 33840955 DOI: 10.4103/ijn.IJN_226_18] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Espinosa-Figueroa JL, Cano-Megías M, Martínez-Miguel P, Velo-Plaza M. Recurrent postinfectious glomerulonephritis: an unusual evolution compatible with C3 glomerulopathy. BMJ Case Rep 2018;2018:bcr-2017-222979. [PMID: 29477994 DOI: 10.1136/bcr-2017-222979] [Reference Citation Analysis]
17 Ozkaya O, Nalcacioglu H, Tekcan D, Genc G, Meydan BC, Ozdemir BH, Baysal MK, Keceligil HT. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy. Pediatr Nephrol 2014;29:1283-7. [PMID: 24464478 DOI: 10.1007/s00467-013-2748-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
18 Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernández-Juarez G, González F, Ávila A, Baltar JM, Díaz M, Alegre R, Elías S, Antón M, Frutos MA, Pobes A, Blasco M, Martín F, Bernis C, Macías M, Barroso S, de Lorenzo A, Ariceta G, López-Mendoza M, Rivas B, López-Revuelta K, Campistol JM, Mendizábal S, de Córdoba SR, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88:1153-60. [PMID: 26221755 DOI: 10.1038/ki.2015.227] [Cited by in Crossref: 79] [Cited by in F6Publishing: 61] [Article Influence: 11.3] [Reference Citation Analysis]
19 Sanghera P, Ghanta M, Ozay F, Ariyamuthu VK, Tanriover B. Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options. Am J Med Sci. 2017;354:533-538. [PMID: 29208248 DOI: 10.1016/j.amjms.2017.03.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
20 Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrología (English Edition) 2017;37:478-91. [DOI: 10.1016/j.nefroe.2017.08.001] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
21 Michels MAHM, Wijnsma KL, Kurvers RAJ, Westra D, Schreuder MF, van Wijk JAE, Bouts AHM, Gracchi V, Engels FAPT, Keijzer-Veen MG, Dorresteijn EM, Volokhina EB, van den Heuvel LPWJ, van de Kar NCAJ. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort. Pediatr Nephrol 2021. [PMID: 34476601 DOI: 10.1007/s00467-021-05221-6] [Reference Citation Analysis]
22 Ramadass M, Ghebrehiwet B, Smith RJ, Kew RR. Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies. J Immunol 2014;192:1220-30. [PMID: 24367026 DOI: 10.4049/jimmunol.1302288] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
23 Rousset-Rouvière C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 2014;29:1107-11. [PMID: 24408225 DOI: 10.1007/s00467-013-2711-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
24 Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol 2015; 4(2): 169-184 [PMID: 25949931 DOI: 10.5527/wjn.v4.i2.169] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
25 Inman M, Prater G, Fatima H, Wallace E. Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis. Clin Kidney J. 2015;8:445-448. [PMID: 26251714 DOI: 10.1093/ckj/sfv044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
26 Zhang Y, Nester CM, Holanda DG, Marsh HC, Hammond RA, Thomas LJ, Meyer NC, Hunsicker LG, Sethi S, Smith RJ. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol. 2013;24:1820-1829. [PMID: 23907509 DOI: 10.1681/asn.2013010045] [Cited by in Crossref: 64] [Cited by in F6Publishing: 41] [Article Influence: 7.1] [Reference Citation Analysis]
27 Mathur M, Sharma S, Prasad D, Garsa R, Singh AP, Kumar R, Beniwal P, Agarwal D, Malhotra V. Incidence and profile of C3 Glomerulopathy: A single center study. Indian J Nephrol 2015;25:8-11. [PMID: 25684865 DOI: 10.4103/0971-4065.136889] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Hosoya M, Kawasaki Y, Maeda R, Sato M, Suyama K, Hashimoto K, Hosoya M. Predictive factors for poor outcome in pediatric C3 glomerulonephritis. Fukushima J Med Sci 2018;64:142-50. [PMID: 30369521 DOI: 10.5387/fms.2018-05] [Reference Citation Analysis]